Contrast-enhanced ultrasound for sentinel node detection in patients with melanoma, breast cancer or head & neck cancer
Key facts
- Where
- Amsterdam, HollandiaSee the site
- Phase
- 2/3. fázis
Where in Hollandia
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAmsterdam, HollandiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
- Trial code
- EU 2024-515259-40-00
- Record updated
- 2024. december 9.
- Original description
To assess the sensitivity and specificity of CEUS for intra-operative SN localization compared to the gold standard (99mTc nanocolloid).Read full original descriptionShow less
Contrast-enhanced ultrasound for sentinel node detection in patients with melanoma, breast cancer or head & neck cancer (N24CUS)
To assess the sensitivity and specificity of CEUS for intra-operative SN localization compared to the gold standard (99mTc nanocolloid).
Inclusion: Aged 18 years or older; Patient has been diagnosed with cancer in the skin (melanoma), breast or head & neck (including melanoma of head and neck area); In case of a melanoma: it should be located in the limbs or head and neck area; Scheduled for a surgical SN procedure at the NKI-AvL; Patient provides written informed consent.
Exclusion: Any known clinically significant acute hypersensitivity reaction to the study medication, such as eggs or egg products; Other contra-indications for Sonazoid contrast agent, including arteriovenous cardiac or pulmonary shunt, serious coronary arterial disease and serious pulmonary disease; Pregnancy.